Visão geral da empresa
A biotechnology enterprise dedicated to drug development, SCYNEXIS, Inc. focuses on creating therapeutic solutions for the treatment and prevention of challenging fungal infections, specifically targeting drug-resistant strains within the United States market. The company operates within the broader Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on niche pharmaceutical solutions rather than mass-market consumer drugs. SCYNEXIS maintains a market capitalization of $44.49M and reports trailing twelve-month revenue of $20.60M, employing a workforce of 18 individuals to execute its research and development objectives. These valuation and revenue figures indicate that the company operates on a micro-cap scale, suggesting a highly specialized operational footprint where limited headcount supports a relatively small revenue base typical of early-stage biotechnology firms.
Saúde financeira
SCYNEXIS reported trailing twelve-month revenue of $20.60M alongside a net income of $-8,609,000, while EBITDA data is not available in the current reporting period. The substantial gap between positive revenue and significant negative net income reveals a cost structure heavily weighted toward research and development expenses, which is characteristic of biotechnology companies investing heavily in pipeline advancement before commercial breakthroughs. Despite the net loss, the company generated free cash flow of $599,625, indicating a degree of financial flexibility that allows for continued operations and capital allocation without immediate reliance on external equity financing. The company's profitability metrics present a mixed picture, with a gross margin of 100.0% reflecting high-value proprietary products, an operating margin of 56.4% showing efficient core business operations, but a profit margin of -41.8% highlighting the impact of non-operating expenses or significant R&D costs on the bottom line. On the balance sheet, SCYNESIS holds $40.03M in cash against $2.17M in debt, resulting in a debt-to-equity ratio of 4.41 which suggests a leveraged position relative to its equity base, though the cash cushion provides substantial coverage for obligations. The current ratio stands at 7.04, a figure that indicates robust short-term liquidity and a strong ability to meet immediate financial liabilities with current assets. Return on Equity is recorded at -16.5% and Return on Assets at -13.4%, metrics that reveal that management has not yet achieved profitability from its equity or asset base, a common scenario for biotechs in the development phase where returns are negative until product commercialization scales.
Avaliação de valorização
The trailing P/E ratio is listed as N/A due to the absence of net income, whereas the forward P/E is -3.02, a negative figure that implies the market is pricing in expectations of future earnings recovery or continued losses in the near term. The price-to-book ratio is 0.88, indicating that the company's market capitalization trades at a discount to its book value, which often suggests a market perception of high risk or undervaluation relative to the tangible assets recorded on the balance sheet. Alternative valuation metrics provide further context, with a price-to-sales ratio of 2.16 suggesting the market values the company based on revenue generation rather than profitability, while the EV/EBITDA metric is N/A due to the lack of positive earnings data. Price action over the past year shows a 52-week high of $1.31 and a 52-week low of $0.56, establishing a trading range where the current price sits below the annual peak but above the annual trough, reflecting significant volatility typical of small-cap biotechnology stocks. The stock exhibits a beta of 1.15, which means its price volatility is 15% higher than the broader market, indicating that the asset will likely experience amplified swings in both upward and downward directions compared to large-cap indices.
Growth & Income
SCYNEXIS recorded a revenue growth rate of 1808.5% year-over-year, while earnings growth is N/A due to the company's ongoing losses. The disparity between explosive revenue expansion and the absence of earnings growth implies that the company is prioritizing market penetration and sales volume to build a pipeline, even at the expense of immediate profitability. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that management chooses to reinvest all available earnings and cash reserves into research, development, and operational scaling rather than distributing income to shareholders. This growth-focused strategy aligns with the biotechnology sector's standard lifecycle, where capital is retained to advance clinical trials and secure regulatory approvals before the company transitions to a cash-flow-positive status.